Market closed

Repare Therapeutics/$RPTX

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Repare Therapeutics

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations. The company derives maximum revenue from Canada.

Ticker

$RPTX
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology

Headquarters

Montreal, Canada

Employees

179
Website
www.reparerx.com

RPTX Metrics

BasicAdvanced
$54M
-
-$1.99
0.71
-

$54M

0.71

$8.49

$1.20

717K

6.447

6.23

0.198

1.465

-23.39%

-41.17%

0.808

0.31

0.31

-0.692

18.19%

-14.30%

326.41%

-7.88%

What the Analysts think about RPTX

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Repare Therapeutics stock.

RPTX Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

RPTX Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

RPTX News

AllArticlesVideos
Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Business Wire·5 days ago
Why Is Repare Therapeutics Stock Trading Lower On Friday?

Why Is Repare Therapeutics Stock Trading Lower On Friday?

Benzinga·1 month ago
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RPTX

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Repare Therapeutics stock?

Repare Therapeutics (RPTX) has a market cap of $54M as of January 15, 2025.

What is the P/E ratio for Repare Therapeutics stock?

The price to earnings (P/E) ratio for Repare Therapeutics (RPTX) stock is 0 as of January 15, 2025.

Does Repare Therapeutics stock pay dividends?

No, Repare Therapeutics (RPTX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Repare Therapeutics dividend payment date?

Repare Therapeutics (RPTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Repare Therapeutics?

Repare Therapeutics (RPTX) has a beta rating of 0.71. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.